Advanced in Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE)

Saul A. Mullen

Heidelberg, VIC, AU 
Advanced in Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE)
Heidelberg, VIC, AU 
OverviewLocationsClinical Research

Overview

Saul Mullen practices in Heidelberg, Australia. Mr. Mullen is rated as an Advanced expert by MediFind in the treatment of Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE). His top areas of expertise are Genetic Epilepsy with Febrile Seizures Plus (GEFS+), Epilepsy, Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE), and Myoclonic Epilepsy.

His clinical research consists of co-authoring 46 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE).

Gender
Male

Locations

Heidelberg, VIC 3084, Australia
Other Locations
Melbourne, VIC, Australia
Parkville, NSW, Australia
Parkville, VIC, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Double-Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Subjects With Epilepsy With a Predictable Seizure Pattern
A Double-Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Subjects With Epilepsy With a Predictable Seizure Pattern
Enrollment Status: Completed
Publish Date: February 03, 2021
Intervention Type: Drug
Study Phase: Phase 2

46 Total Publications

Cell-type-informed genotyping of mosaic focal epilepsies reveals cell-autonomous and non-cell-autonomous disease-associated transcriptional programs.
Cell-type-informed genotyping of mosaic focal epilepsies reveals cell-autonomous and non-cell-autonomous disease-associated transcriptional programs.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: July 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Mullen's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile